After a change in screening guidelines, the incidence increased across the state, surpassing the national trend. A new study ...
Advanced prostate cancer cases in California are rising faster than the national average, according to a UCSF study. Experts ...
Quality of life, treatment impact and duration, and the importance of individualized therapy are at the center of ...
Pfizer’s Talzenna in combi with Xtandi improves survival outcomes in metastatic castration resistant prostate cancer: New York Saturday, February 15, 2025, 11:00 Hrs [IST] Pfize ...
Sebastian Kaulitzki – stock.adobe.com “Without screening, the number of men diagnosed with advanced prostate cancer – when treatments are less effective – increases fast.” Fox News ...
Updated data from the Phase III TALAPRO-2 trial show that the combination of Talzenna (talazoparib) and Xtandi (enzalutamide) significantly improves overall survival in patients with metastatic ...
Prostate cancer cells usually require male androgen hormones, such as testosterone, to grow. Androgen deprivation therapy ...
The 18-gene MyProstateScore 2.0 (MPS2) test using first-catch non-digital rectal examination (DRE) urine is highly se ...
Data on enfortumab vedotin plus pembrolizumab for advanced bladder cancer, along with updates on antibody-drug conjugates, ...
The incidence of advanced prostate cancer in California rose markedly in the decade since doctors stopped routinely screening all men for the disease, according to a new study.
NEW YORK, NY, USA I 13, 2025 I Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback